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Background: Although idiopathic nonspecific interstitial pneumonia (NSIP) was initially identi-
fied as a provisional diagnosis, the 2008 American Thoracic Society Project concluded that idio-
pathic NSIP is a distinct form of idiopathic interstitial pneumonia. However, an association
between idiopathic NSIP and autoimmune diseases still attracts interest. In this context,
a recent study proposed an intriguing concept that idiopathic NSIP is the pulmonary manifes-
tation of undifferentiated connective tissue disease (UCTD). However, this has not been
confirmed in a large number of patients with idiopathic NSIP. The present study was conducted
to investigate the proportion and characteristics of patients with idiopathic NSIP who meet the
criteria for UCTD.
Methods: We reviewed 47 consecutive patients with idiopathic NSIP and examined whether
they met prespecified criteria for UCTD. Furthermore, we compared the clinicalstitial pneumonia; UIP, usual interstitial pneumonia; DIP, desquamative interstitial pneumonia; IIP,
, idiopathic pulmonary fibrosis; UCTD, undifferentiated connective tissue disease; CTD, connective
dermatomyositis; SS, primary Sjo¨gren syndrome; RA, rheumatoid arthritis; SLE, systemic lupus; SSc,
lar lavage.
3) 435 2263; fax: þ81 (53) 435 2449.
c.jp (T. Suda).
0 Elsevier Ltd. All rights reserved.
1528 T. Suda et al.characteristics between patients fulfilling the UCTD criteria (UCTD-NSIP) and those not
meeting them (Non-UCTD-NSIP).
Results: Of 47 patients with idiopathic NSIP, 22 (47%) met the UCTD criteria. Common symp-
toms associated with connective tissue diseases (CTDs) were skin change (50%) and Raynaud’s
phenomenon (41%) in UCTD-NSIP. UCTD-NSIP showed a female predominance and significantly
higher percentages of lymphocytes with a lower CD4/CD8 ratio in bronchoalveolar lavage than
Non-UCTD-NSIP. Interestingly, UCTD-NSIP had a significantly better survival than Non-UCTD-
NSIP.
Conclusions: Idiopathic NSIP included subjects who fulfilled the UCTD criteria, and these
subjects had different clinical characteristics with significantly better outcome than those
who did not meet the criteria. These data suggest that a part, but not all, of patients with idio-
pathic NSIP show CTD-like features with a distinct prognosis.
ª 2010 Elsevier Ltd. All rights reserved.Introduction
Nonspecific interstitial pneumonia was originally described
as a pathologic pattern distinct from other defined inter-
stitial pneumonias, such as usual interstitial pneumonia
(UIP) and desquamative interstitial pneumonia (DIP), by
Katzenstein and Fiorelli.1 NSIP has also been shown to be
associated with a variety of conditions, including connec-
tive tissue diseases (CTDs), drug reactions, and organic dust
exposures.1e6 Thus, the 2002 Joint Statement of American
Thoracic Society (ATS) and European Respiratory Society
(ERS) on the classification of idiopathic interstitial pneu-
monias (IIPs) described idiopathic NSIP as a provisional
diagnosis to be further defined.7 Interestingly, recent
studies have demonstrated that NSIP is the most common
histologic pattern in CTD-associated interstitial pneumo-
nias,2e4,8,9 and that patients with idiopathic NSIP often
exhibit CTD-like features, such as autoantibodies.10,11 The
precise relationship between idiopathic NSIP and CTDs
remains to be further clarified.
Kinder et al. recently proposed a very interesting
hypothesis: idiopathic NSIP is the pulmonary manifestation
of undifferentiated connective tissue disease (UCTD).12
UCTD is characterized by the presence of signs and symp-
toms suggestive of a systemic autoimmune disease but they
do not meet the criteria for defined CTDs, such as systemic
lupus erythematosus (SLE), Sjo¨gren syndrome (SS), and
rheumatoid arthritis (RA).13e17
However, no validated criteria for the diagnosis of UCTD
have been established so far. Kinder et al. proposed pre-
specified criteria for UCTD and investigated the proportion
and characteristics of patients fulfilling their UCTD criteria
in IIPs.12 They showed that IIP patients who met the UCTD
criteria had distinct features, including a female predomi-
nance, high incidence of ground-glass opacity on high-
resolution computed tomography (HRCT), and NSIP pattern
on surgical lung biopsy. Remarkably, the majority of
patients with idiopathic NSIP (88%) met the UCTD criteria,
while only a small proportion (5%) of those with idiopathic
pulmonary fibrosis (IPF) fulfilled the criteria. Thus, Kinder
et al. concluded that idiopathic NSIP appears to be an
autoimmune disease, the pulmonary manifestation of
UCTD. This hypothesis is attractive but needs to be
confirmed. In particular, the study of Kinder et al. included
only a small number of patients with idiopathic NSIP (17cases). In contrast to Kinder’s study, the ATS project
recently supported the notion that idiopathic NSIP is
a distinct clinical entity of IIPs.18 Out of the original 306
cases of idiopathic NSIP, however, only 67 cases were
identified as definite or probable idiopathic NSIP by
a dynamic integrated multidisciplinary approach in the ATS
project. This project also mentioned several future issues
to be investigated for further confirmation of the clinical
entity of idiopathic NSIP, one of which is to determine
whether idiopathic NSIP is a manifestation of an autoim-
mune disease.
The present study was conducted to investigate the
proportion of patients with idiopathic NSIP fulfilling the
UCTD criteria proposed by Kinder et al. in a larger pop-
ulation, and to define the clinical characteristics of those
patients. Furthermore, we attempted to clarify the signif-
icance of UCTD diagnosis in idiopathic NSIP.Patients and methods
Patients and diagnostic criteria
We studied 62 consecutive patients with idiopathic NSIP
who underwent open or thoracoscopic lung biopsy at our
facilities from 1990 to 2009. The diagnosis of idiopathic
NSIP was based on history, physical examination, HRCT,
and histologic examination, in accordance with the ATS/
ERS consensus classification.7 At the initial diagnosis, none
of the patients fulfilled the American College of Rheu-
matology (ACR) criteria for defined CTDs, such as RA, SS,
systemic sclerosis (SSc), polymyositis/dermatomyositis
(PM/DM), SLE, or mixed connective tissue disease (MCTD).
The study protocol was approved by the Ethical
Committee of the Hamamatsu University School of
Medicine.
We used the criteria for UCTD proposed by Kinder et al. as
defined in Table 1. Patients were diagnosed as having UCTD if
theyhadat least one of symptomsassociatedwithCTDs and at
least one evidence of systemic inflammation listed in Table 1.
Because there was the possibility of false-negative diagnosis
of patients for whom fewer items listed as evidence of
systemic inflammation in Table 1 were measured, the study
subjects included patients with at least four items assessed as
evidence of systemic inflammation.
Table 1 Diagnostic criteria for undifferentiated connec-
tive tissue disease.
Diagnostic criteria Presence of
Symptoms associated
with connective
tissue disease
At least one of the
following symptoms:
1. Raynaud’s phenomenon
2. Arthralgias/multiple
joint swelling
3. Photosensitivity
4. Unintentional weight loss
5. Morning stiffness
6. Dry mouth or dry eyes
(sicca features)
7. Dysphagia
8. Recurrent unexplained fever
9. Gastroesophageal reflux
10. Skin changes (rash)
11. Oral ulceration
12. Nonandrogenic alopecia
13. Proximal muscle weakness
Evidence of systemic
inflammation in the
absence of infection
Positive findings for at least
one of the following:
1. Antinuclear antigen
2. Rheumatoid factor
3. Anti-SCL 70 antibody
4. SS-A or SS-B antibody
5. Jo-1 antibody
6. Sedimentation rate
(>two times normal),
C-reactive protein
* Criteria are derived from Reference 12.
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Clinical data, including sex, age, smoking history, symp-
toms, treatment and outcome were obtained from patient
medical records. Laboratory findings, pulmonary function
tests, and bronchoalveolar lavage (BAL) data at the time of
surgical lung biopsy were also recorded.Pathological review
Lung biopsy specimens were independently reviewed by
three pathologists (T.V.C., Y.N., S.I.) who were unaware
of the clinical or physiological findings. In 8 cases, initial
histological classification differed between the patholo-
gist, but a consensus opinion on the overall histopatho-
logical pattern was reached. Histological classification
was based on the previously published criteria for IIPs
from the ATS/ERS.7 In addition, the degree of each
pathologic finding was semiquantitatively scored (absent
0, mild 1, moderate 2, and marked 3) by two pathologists
(Y.N., S.I.). The pathologic findings scored included the
following: alveolar inflammation, intra-alveolar macro-
phages, organizing pneumonia, germinal centers,
fibrosis, fibroblastic foci, honeycombing, and pleural
changes.High-resolution computed tomography (HRCT)
HRCT examination of the lungs was performed on 1.0- or
1.5-mm-thick sections to evaluate radiographic abnormali-
ties. The HRCT images were reviewed for the presence and
distribution of each of the following sign: ground-glass
attenuation, airspace consolidation, interlobular septal
thickening, intralobular reticular opacity, thickening of
bronchovascular bundles, traction bronchiectasis, honey-
combing, and cysts.
Statistical analysis
For two-group comparisons involving binary data, we used
the chi-square test. Comparisons involving continuous data
were made using ManneWhitney U test. The interobserver
correlation was analyzed using Pearson’s correlation coef-
ficient. Cumulative survival probabilities were estimated
using the KaplaneMeier method. The log-rank test was used
to compare survival among the groups of patients. Statis-
tical analyses were performed using JMP Start Stastitics
(SAS Institute Inc., NC, USA). A p value <0.05 was consid-
ered significant.
Results
Patient characteristics
Of the original 62 NSIP patients, six patients were excluded,
because they developed PM/DM during the observation
period following initial diagnosis. These six patients had
fulfilled the UCTD criteria at the initial NSIP diagnosis.
Among the remaining 56 patients, 47 had adequate data
with  four items as evidence of systemic inflammation
among the diagnostic criteria for UCTD. Of these 47
patients, 22 (47%) met the criteria for UCTD proposed by
Kinder et al.
Clinical characteristics of patients who met the
criteria for UCTD (UCTD-NSIP) and those who did not
meet them (Non-UCTD-NSIP) are shown in Table 2. The
median age for the patients of UCTD-NSIP was similar to
that for those of Non-UCTD-NSIP. The proportion of males
and current smokers tended to be lower in UCTD-NSIP
than in Non-UCTD-NSIP, but the differences were not
statistically significant. Respiratory symptoms or signs
did not significantly differ between them. In UCTD-NSIP,
the most common symptom associated with CTDs was
skin change (50%), followed by Raynaud’s phenomenon
(41%) and arthralgias/joint swelling (23%). Fourteen
patients with UCTD-NSIP (64%) had  two symptoms. In
Non-UCTD-NSIP, the symptoms associated with CTDs were
rarely observed.
Laboratory findings
No significant difference was found in the serum levels of
lactate dehydrogenase (LDH), C-reactive protein (CRP), KL-
6, or surfactant protein-D (SP-D) between UCTD-NSIP and
Non-UCTD-NSIP (Table 3). There were trends for creatine
phosphokinase (CPK) and sedimentation rate to be higher in
1530 T. Suda et al.UCTD-NSIP than in Non-UCTD-NSIP, but the differences did
not reach statistical significance.
Among autoantibodies, anti-nuclear antibody was most
frequently found in UCTD-NSIP (68%) (Table 3). The inci-
dence of positive anti-nuclear antibody was significantly
higher in UCTD-NSIP than in Non-UCTD-NSIP (p Z 0.0262),
but the titers were not significantly different (median
[range], 120 [40e320] and 120 [40e1280], respectively).
The positive rates of rheumatoid factor of UCTD-NSIP were
similar to those of Non-UCTD-NSIP. Anti-Jo1 antibody and
PR3-ANCA were present exclusively in UCTD-NSIP.
No significant difference was found in the results of
pulmonary function tests between UCTD-NSIP and Non-
UCTD-NSIP, although FVC and diffusion capacity for carbon
monoxide (DLco) tended to be lower in UCTD-NSIP than in
Non-UCTD-NSIP (Table 3).
BAL was performed in 17 and 23 patients with UCTD-NSIP
and Non-UCTD-NSIP, respectively. The percentage of BAL
lymphocytes was significantly higher in UCTD-NSIP than in
Non-UCTD-NSIP (p Z 0.0424) (Table 3). In addition, the
percentage of BAL macrophages and the CD4/CD8 ratio of
BAL lymphocytes were significantly lower in UCTD-NSIP
than in Non-UCTD-NSIP (p Z 0.0328 and p Z 0.0145,
respectively).Table 2 Clinical characteristics of NSIP patients who fulfill
compared with those who do not.
Characteristics UCTD-NSIP
patientsa (n Z 22
Age, yr 57 (24e77)c
Gender, male/female 8/14
Smoking habit, n
Current/former/never 3/7/12
Observation period, yr 3.8 (0.6e17.2)
Symptoms and signs, n (%)
Respiratory
Cough 16 (73)
Dyspnea 4 (18)
Fine crackles 17 (77)
Clubbing 2 (9)
Systemic
Skin change (rash) 11 (50)
Raynaud’s phenomenon 9 (41)
Arthralgias/joint swelling 5 (23)
Dysphagia 4 (18)
Morning stiffness 4 (18)
Proximal muscle weakness 4 (18)
Sicca symptoms 3 (14)
Recurrent fever 3 (14)
Unintentional weight loss 1 (5)
Photosensitivity 0 (0)
GERD 0 (0)
Oral ulceration 0 (0)
Alopecia (nonandrogenic) 0 (0)
UCTD, undifferentiated connective tissue disease: GERD, gastroesoph
a NSIP patients who fulfill the criteria for UCTD.
b NSIP patients who do not fulfill the criteria for UCTD.
c Median (Range).Pathological findings
Cellular NSIP was histologically diagnosed in 2 of 22 patients
with UCTD-NSIP and 3 of 25 those with Non-UCTD-NSIP (9.1%
vs. 12.0%, respectively), and the remaining patients had
fibrotic NSIP (Table 4). Regarding each pathological finding
listed in Table 4, there was no significant difference in its
score, although the scores of germinal center tended to be
higher in UCTD-NSIP than in Non-UCTD-NSIP (p Z 0.0914).
Interobserver correlation in the score of each finding was
statistically significant, but the r-values were not high
(0.481e0.667).Radiologic findings
As shown in Table 4, ground-glass attenuation and traction
bronchiectasis were generally (>90%) seen in both UCTD-
NSIP and Non-UCTD-NSIP. Airspace consolidation and
thickening of bronchovascular bundles were more common
in UCTD-NSIP than in Non-UCTD-NSIP (p Z 0.0534 and
p Z 0.0586, respectively). Regarding distributions of
abnormalities, lower zone predominance was prominent in
both UCTD-NSIP and Non-UCTD-NSIP.the criteria for undifferentiated connective tissue disease
)
Non-UCTD-NSIP
patientsb (n Z 25)
P value
58 (38e83) n.s.
14/11 n.s.
10/6/9 n.s.
4.1 (0.6e13.8) n.s.
15 (60) n.s.
5 (20) n.s.
19 (76) n.s.
2 (8) n.s.
1 (4) < 0.0001
0 (0) < 0.0001
1 (4) 0.0477
0 (0) 0.0258
0 (0) 0.0258
0 (0) 0.0258
1 (4) n.s.
0 (0) 0.0287
0 (0) n.s.
0 (0) n.s.
1 (4) n.s.
0 (0) n.s.
0 (0) n.s.
ageal reflux disease; n.s., not significant.
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Most of the patients were treated with corticosteroid or
corticosteroid plus immunosuppressive agents (UCTD-NSIP
15 patients [77%]; Non-UCTD-NSIP 20 patients [80%]) (TableTable 3 Laboratory and bronchoalveolar lavage findings
of NSIP patients who fulfill the criteria for undifferentiated
connective tissue disease compared with those who do not.
Characteristics UCTD-
NSIPa
Non-UCTD
-NSIPb
P value
LDH, IU/L 333  149c 293  104 n.s.
CPK, IU/L 252  415 94  50 n.s.
CRP, mg/dL 0.87  1.00 0.60  1.05 n.s.
Sedimentation
rate, mm/hr
38  7 22  16 n.s.
KL-6, U/mL 1690  1194 1792  1410 n.s.
SP-D, ng/mL 261  203 263  132 n.s.
Anti-nuclear
antibody
15/22 (68)d 9/25 (36) 0.0262
Rhematoid factor 3/21 (14) 4/25 (16) n.s.
Anti-SCL 70 antibody 0/19 (0) 0/15 (0) n.s.
Anti-SSA antibody 3/21 (14) 1/16 (6) n.s.
Anti-SSB antibody 0/21 (0) 0/16 (0) n.s.
Anti-Jo1 antibody 2/19 (11) 0/16 (0) n.s.
Anti-centromere
antibody
0/16 (0) 0/6 (0) n.s.
Anti-RNP antibody 1/14 (7) 0/12 (0) n.s.
Anti-double strand
DNA antibody
1/18 (6) 0/17 (0) n.s.
Anti-Sm antibody 0/10 (0) 0/9 (0) n.s.
MPO-ANCA 0/12 (0) 0/13 (0) n.s.
PR3-ANCA 1/12 (8) 0/14 (0) n.s.
PaO2 on room
air, Torr
78  13 78  14 n.s.
FVC, % predicted 61  15 70  22 n.s.
DLco, % predicted 60  17 72  28 n.s.
Bronchoalveolar
lavage (BAL)
n Z 17 n Z 23
Total cell
count, x 105/mL
2.62  1.86 2.32  2.07 n.s.
Cellular profile, %
Macrophages 61.6  30.0 84.1  9.7 0.0328
Lymphocytes 28.9  29.1 11.4  9.8 0.0424
Neutrophils 5.6  8.2 2.7  2.7 n.s.
Eosinophils 3.2  4.0 2.1  2.8 n.s.
CD4/CD8 ratio
of BAL lymphocytes
1.03  1.20 2.49  2.83 0.0145
UCTD, undifferentiated connective tissue disease; LDH, lactate
dehydrogenase; SP-D, surfactant protein D; MPO-ANCA, myelo-
peroxidase antineutrophil cytoplasmic autoantibody; PR3-
ANCA, proteinase 3-antineutrophil cytoplasmic antibody; VC,
vital capacity; FEV1, forced vital capacity in 1 s; DLco, diffusion
capacity for carbon monoxide; BAL, bronchoalveolar lavage;
n.s., not significant.
a NSIP patients who fulfill the criteria for UCTD.
b NSIP patients who do not fulfill the criteria for UCTD.
c Mean  SD.
d The number of positive results/the number tested (%).5). Among the immunosuppressive agents, cyclosporine was
most commonly given to the both groups. There was no
significant difference in the percentage of patients receiving
immunosuppressive agents or duration of the therapy
between the two groups. Only one patient (5%) with UCTD-
NSIP died of respiratory failure during the observation
period, while eight patients (32%) with Non-UCTD-NSIP
patients died. The difference was statistically significant
(pZ 0.0170). No patients with cellular NSIP died during the
observation period in UCTD-NSIP or Non-UCTD-NSIP.
Survival
A comparison of survival curves between the two groups is
shown in Fig. 1. Patients with UCTD-NSIP had a significantly
better survival rate than those with Non-UCTD-NSIP (5-year
survival, 100% vs. 58%, respectively; p Z 0.0092).
Discussion
The present study demonstrated that about half of patients
with idiopathic NSIP met the criteria for UCTD proposed by
Kinder et al. Comparing NSIP patients fulfilling the criteria
for UCTD (UCTD-NSIP) with those who did not meet the
criteria (Non-UCTD-NSIP), patients with UCTD-NSIP had
a significantly higher percentage of BAL lymphocytes with
a lower CD4/CD8 ratio. Interestingly, patients with UCTD-
NSIP had a significantly better survival than those with Non-
UCTD-NSIP. These data suggest that UCTD diagnosis based
on the criteria of Kinder et al. is associated with favorable
prognosis in idiopathic NSIP.
Between patients with UCTD-NSIP and those with
NoneUCTD-NSIP, besides the BAL findings and prognosis,
several differences were noted. A female predominance
(64%) was found in UCTD-NSIP, but not in Non-UCTD-NSIP. A
large proportion of patients with UCTD-NSIP presented with
two or more CTD-associated symptoms and/or signs, while
those with Non-UCTD-NSIP scarcely had them. On HRCT,
airspace consolidation and thickening of bronchovascular
bundles tended to be found more frequently in UCTD-NSIP
than inNon-UCTD-NSIP (68.2%vs. 40.0%,pZ0.0534;63.6% vs.
36.0, p Z 0.0586, respectively) Taken together, these data
suggest that patients fulfilling the UCTD criteria of Kinder
et al. may have distinct characteristics in idiopathic NSIP.
We confirmed the study of Kinder et al. showing that
idiopathic NSIP included subjects fulfilling their UCTD
criteria. However, there were several discrepancies
between this previous work and our study. First, the
proportion of patients who met the criteria of Kinder et al.
was lower in our NSIP patients than in this previous work (47%
vs. 88%, respectively). Kinder et al. proposed the interesting
notion that the clinical entity of idiopathic NSIP is the lung
manifestation of UCTD, because most of their patients with
idiopathic NSIP met the UCTD criteria.12 However, our
observations suggest that idiopathic NSIP consisted of two
populations with distinct prognoses: patients fulfilling and
those not fulfilling the UCTD criteria. Second, the profiles of
symptoms and signs associated with CTDs were different.
Kinder et al. reported that the most common symptoms and
signs were GERD (65%) and arthralgias/joint swelling (64%).
However, skin changeandRaynaud’s phenomenonweremost
Table 4 Pathological and radiologic findings of NSIP patients who fulfill the criteria for undifferentiated connective tissue
disease compared with those who do not.
Features UCTD-NSIPa Non-UCTD-NSIPb P value
Pathological findings
Cellular NSIP/Fibrotic NSIP 2/20 3/22 n.s.
Alveolar wall inflammation 2.0  0.4c 1.9  0.6 n.s.
Intra-alveolar macrophages 0.8  0.4 0.8  0.8 n.s.
Organizing pneumonia 0.8  0.8 0.6  0.7 n.s.
Germinal center 0.7  1.2 0.3  0.5 n.s.
Fibrosis 2.2  0.6 2.2  0.8 n.s.
Honey combing 0.3  0.8 0.6  0.3 n.s.
Pleural lesion 0.3  0.9 0.3  0.9 n.s.
Radiologic findings
Ground-glass attenuation, % 95.5 92.0 n.s.
Airspace consolidation, % 68.2 40.0 0.0534
Interlobular septal thickening, % 22.7 40.0 n.s.
Intralobular reticular opacity, % 77.2 72.0 n.s.
Thickening of bronchovascular bundles, % 63.6 36.0 0.0586
Traction bronchiectasis, % 95.5 96.0 n.s.
Honeycombing, % 4.5 12.0 n.s.
Cysts, % 4.5 8.0 n.s.
Lower zone predominance, % 77.3 68.0 n.s.
UCTD, undifferentiated connective tissue disease; n.s., not significant.
a NSIP patients who fulfill the criteria for UCTD.
b NSIP patients who do not fulfill the criteria for UCTD.
c Scores 0-3, Mean  SD.
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41%, respectively). The reason for these discrepancies is
unknown. The study of Kinder et al. included only 17 patients
with idiopathic NSIP, whereas we examined a relatively large
number of patients (47 cases). In addition, there was a wide
ethnic dissimilarity between the two studies. These differ-
ences in study population may be partly related to the
discrepancies. To resolve this issue, future studies on a larger
series of patients with idiopathic NSIP are necessary.
Because the disease entity of UCTD has not been fully
established and there has been no validation of the criteria
of Kinder et al., interpretations of our observations andTable 5 Treatment and outcome of NSIP patients who fulfill
compared with those who do not.
UCTD-NSIPa (n Z 22
Treatment, n (%)
Corticosteroids alone 6 (36)
Corticosteroids þ
immunosuppressive agents
9 (41)
Cyclosporine 6
Cyclophosphamide 2
Azathioprine 1
Duration of therapy, yr 3.5 (0.6e15.2)c
Death due to respiratory
failure, n (%)
1 (5)
n.s., not significant.
a NSIP patients who fulfill the criteria for UCTD.
b NSIP patients who do not fulfill the criteria for UCTD.
c Mean  SD.those of Kinder et al. should be made with great caution.
Initially, UCTD was defined as systemic autoimmune disor-
ders with signs and symptoms that do not sufficiently fulfill
the accepted classification criteria for the defined CTDs.13
Thus, UCTD was also considered a latent or subclinical
phase of the defined CTDs, developing overt CTDs later.19,20
However, Mosca et al. demonstrated that only a small
population of patients with UCTD developed the defined
CTDs, in particular, early in their clinical course.15e17 Thus,
they concluded that UCTD is a clinical entity distinct from
other defined CTDs. In contrast, other studies reported the
relatively high prevalences (35e68%) of progression tothe criteria for undifferentiated connective tissue disease
) Non-UCTD-NSIPb (n Z 25) P value
10 (40) n.s.
10 (40) n.s.
7
1
2
4.0 (1.2e13.6) n.s.
8 (32) 0.0170
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Figure 1 Survival curves of NSIP patients. Patients fulfilling
the criteria of undifferentiated connective tissue disease
(UCTD-NSIP) have a significantly better survival rate than those
who do not fulfill (Non-UCTD-NSIP) (log-rank, p Z 0.0092).
UCTD diagnosis in idiopathic NSIP 1533defined CTDs during the first and second years of follow-up
in patients with UCTD.14,19,21e23 Considering these condi-
tions, Mosca et al. proposed criteria for UCTD as follows: (1)
signs and symptoms suggestive of a CTD, but not fulfilling
the criteria for any defined CTDs, (2) positive antinuclear
antibodies, and (3) a disease duration of at least 3 years.24
Importantly, the criteria of Kinder et al. used in the present
study have several differences, compared with those of
Mosca et al. First, the criteria of Kinder et al. does not
include disease duration. As a result, patients with the
defined CTDs that had not fulfilled the criteria for the
defined CTDs at the initial visit, but that met the criteria of
Kinder et al. for UCTD, are incorrectly diagnosed as UCTD.
In those patients, anti-inflammatory and immunosuppres-
sive treatment for NSIP often masks the later development
of the overt defined CTDs. Second, although the criteria of
Kinder et al. included sedimentation rate (>two times
normal) and C-reactive protein as evidence of systemic
inflammation (Table 1), these measurements are highly
non-specific. Third, similarly, GERD listed in symptoms
associated with CTDs (Table 1), which was the most
common symptom in the study of Kinder et al., is not
specific for CTDs. Further studies will be needed to fully
define UCTD and to develop validated criteria for this
disease. At present, it is, at least, true that the criteria of
Kinder et al. pick out patients who have symptoms and/or
signs that are suggestive of autoimmune disorders. In this
context, an alternative implication of our results is that
a part, but not all, of patients with idiopathic NSIP had CTD-
like features but did not fulfill the criteria for the defined
CTDs, and that those patients with CTD-like features
showed distinct favorable prognosis. Possibly, idiopathic
NSIP with CTD-like features may include true UCTD and
early phases of the defined CTDs. Indeed, six (9.7%) of our
62 patents initially diagnosed with idiopathic NSIP pro-
gressed to PM/DM during the observation periods, and all
the six patients had fulfilled the UCTD criteria but had not
met the PM/DM criteria at the first visit.
Besides the lack of validation of the UCTD criteria we
used, there are several other limitations to the present
study. First, this was a retrospective study, so there were
selection and recall biases. Second, although the presentstudy included a relatively large number of patients with
idiopathic NSIP, the sample size was still too small to
determine the precise prevalence and clinical characteris-
tics of those who meet the UCTD criteria.
In conclusion, we showed that idiopathic NSIP included
subjects who fulfilled the UCTD criteria proposed by Kinder
et al. Additionally, subjects fulfilling the UCTD criteria had
different clinical characteristics with significantly better
outcome than those who did not meet the criteria. These
data suggest that a part of patients with idiopathic NSIP
showed CTD-like features with a distinct prognosis. Future
studies will be required to validate our observations.Acknowledgement
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